“Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma” has been added to your cart. View cart

Article: A new kid on the block: Luspatercept in low-risk myelodysplastic syndrome

€3.03

SKU: product-article-40916 Category: General

Description
Reviews (0)

Description

A new kid on the block: Luspatercept in low-risk myelodysplastic syndrome

Reviews

There are no reviews yet.

Be the first to review “Article: A new kid on the block: Luspatercept in low-risk myelodysplastic syndrome”

You must be logged in to post a review.

Top

Article: A new kid on the block: Luspatercept in low-risk myelodysplastic syndrome

Description

Reviews

Related products

Article: Highlights in urologic cancer

Article: Highlights in digestive oncology

Article: Highlights in melanoma

Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer